Answers are grounded in this paper and cite their sources.
= 0.05). There is a low rate of treatment failure in Australian BU patients treated with rifampin-based oral combination antibiotic therapy. Our study raises the possibility that treatment failure risk may be increased in males, those with a body weight of >90 kg, those with immune suppression, and those taking rifampin-clarithromycin antibiotic regimens, but future pharmacokinetic and pharmacodynamics studies are required to determine the validity of these hypotheses.
No takes yet. Share an insight, caveat, or question.
O’Brien et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: